Latest News about MKKGY
Recent news which mentions MKKGY
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
February 16, 2025
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
December 06, 2023
From Benzinga
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
September 26, 2023
From Benzinga
From Benzinga
From Benzinga
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
June 20, 2023
From Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
April 18, 2023
From Benzinga
From Benzinga
From Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
March 23, 2023
From Benzinga
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
January 20, 2023
From Benzinga
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
January 03, 2023
From Benzinga
Mersana Inks Cancer Therapy Development Deal With Merck Germany
December 23, 2022
From Benzinga
From Benzinga
Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug
October 19, 2022
Tickers
MKKGY
From Benzinga
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers
October 11, 2022
From Benzinga
From Motley Fool
From Benzinga
From Motley Fool
Cathie Wood Can't Get Enough of These 2 Biotech Stocks
March 31, 2022
From Motley Fool
TSM Looks To Hire Over 8,000 People In 2022
January 24, 2022
From Benzinga
From InvestorPlace
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
November 18, 2021
From Benzinga
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
September 30, 2021
From Benzinga
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
September 21, 2021
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.